Palbociclib/Pabociclib/Palbociclib Research and Development Corporation

Palbociclib is developed and produced by Pfizer, one of the world's leading pharmaceutical companies. It was founded in 1849 and is headquartered in New York, USA. Palbocicillin was released in20152Menstruation USFDA< span> was approved for marketing, and was approved for marketing by the State Food and Drug Administration of China in 20188, and has been included in the national medical insurance.

Palmoxicillin is indicated for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy or fulvestrant for the treatment of patients with disease progression after endocrine therapy.

Palboxicillin is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of signaling pathways that lead to cell proliferation. In vitro, palbocicillin reduces cell proliferation in estrogen receptor (ER)-positive breast cancer cell lines by preventing cells from entering the S phase of the cell cycle. Treatment of breast cancer cell lines with the combination of palbocicillin and antiestrogen resulted in reduced retinoblastoma(Rb) protein phosphorylation, resulting in reduced E2F expression and signaling, and increased growth arrest compared with treatment with each drug alone. In vitro treatment of ERpositive breast cancer cell lines with the combination of palbocicillin and antiestrogen compared with each drug alone resulted in increased cellular senescence that persisted for up to 6days after removal of palbocicillin and was more severe if antiestrogen treatment was continued. In vivo studies using a patient-derived ERpositive breast cancer xenograft model demonstrated that the combination of palbocicillin and letrozole increased the inhibition of Rb phosphorylation, downstream signaling, and tumor growth compared with each drug alone. In vitro, in the presence or absence of antiestrogens, withPalbocilibtreated human bone marrow mononuclear cells do not senescence and resume proliferation after palbocilib is discontinued. Original drugs in Hong Kong cost around 1 million, while generic drugs cost around 7more than 7more than 4 more than 1,000 per box. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.